KT501

· Kali Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for KT501, covering 2026-03-10 to 2026-03-10. Get the full timeline:

Most recent: Clinical Trial Update: A First-in-human Study of KT501 Administered Subcutaneously to Patients With Rheumatoid Arthritis (RA). [Phase 1]